Real-world treatment patterns and clinical characteristics in patients with moderate-to-severe systemic lupus erythematosus: an analysis of the SLE Prospective Observational Cohort Study (SPOCS)
Objectives Systemic lupus erythematosus (SLE) is a disease with heterogeneous treatment patterns largely based on organ involvement and disease severity. The SLE Prospective Observational Cohort Study (SPOCS) collected data worldwide over 3 years from patients with moderate-to-severe SLE. We report...
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2025-01-01
|
| Series: | Lupus Science and Medicine |
| Online Access: | https://lupus.bmj.com/content/12/1/e001336.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823860917230632960 |
|---|---|
| author | Raj Tummala Richard A Furie Laurent Arnaud Eric F Morand Martin Aringer Stephanie Chen Barnabas Desta Alberta Hoi Bo Ding Christine Peschken Jonatan Hedberg Tina Grünfeld Eén Alessandro Sorrentino Danuta Kielar |
| author_facet | Raj Tummala Richard A Furie Laurent Arnaud Eric F Morand Martin Aringer Stephanie Chen Barnabas Desta Alberta Hoi Bo Ding Christine Peschken Jonatan Hedberg Tina Grünfeld Eén Alessandro Sorrentino Danuta Kielar |
| author_sort | Raj Tummala |
| collection | DOAJ |
| description | Objectives Systemic lupus erythematosus (SLE) is a disease with heterogeneous treatment patterns largely based on organ involvement and disease severity. The SLE Prospective Observational Cohort Study (SPOCS) collected data worldwide over 3 years from patients with moderate-to-severe SLE. We report real-world patterns of medication use in patients enrolled in SPOCS.Methods Data were collected at study entry; patients were followed twice annually according to local practice. Disease activity (SLE Disease Activity Index 2000 (SLEDAI-2K)), average oral glucocorticoid dose and use of other treatments—specifically antimalarials, biologics and immunosuppressants—were measured over time. Subgroup analyses were stratified by baseline interferon gene signature (IFNGS) status and disease activity (SLEDAI-2K) status.Results Patient demographics and baseline characteristics were similar among subgroups; the majority of patients were on antimalarials (n=670; 81.1%), followed by glucocorticoids (n=537; 65.0%), immunosuppressants (n=453; 54.8%) and biologics (n=175; 21.2%). In the overall population, median (IQR) SLEDAI-2K scores decreased within 12 months (baseline: 8.0 (6.0–12.0); 12 months: 4.0 (2.0–8.0)) and remained stable thereafter. The mean (SD) daily oral glucocorticoid dose increased by 6 months (baseline: 6.0 (7.09); 6 months: 9.8 (8.67)) and remained stable thereafter. The proportion of patients who were on glucocorticoid doses >5 mg/day ranged from ~20% to 33% throughout the study. In subgroup analyses, patients with high IFNGS and high disease activity state (HDAS) at baseline used more immunosuppressants and glucocorticoids compared with those with low IFNGS and non-HDAS at baseline.Conclusions These findings underscore that SLE therapy is still often unable to reach goals as recommended by the European Alliance of Associations for Rheumatology, both with regard to glucocorticoid use and disease activity, suggesting that there is an unmet need for new treatment options for patients with SLE.Trial registration number NCT03189875; 16 June 2017. |
| format | Article |
| id | doaj-art-ad1f74e123a04d28a638c3c13449f4ce |
| institution | Kabale University |
| issn | 2053-8790 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Lupus Science and Medicine |
| spelling | doaj-art-ad1f74e123a04d28a638c3c13449f4ce2025-02-10T09:00:08ZengBMJ Publishing GroupLupus Science and Medicine2053-87902025-01-0112110.1136/lupus-2024-001336Real-world treatment patterns and clinical characteristics in patients with moderate-to-severe systemic lupus erythematosus: an analysis of the SLE Prospective Observational Cohort Study (SPOCS)Raj Tummala0Richard A Furie1Laurent Arnaud2Eric F Morand3Martin Aringer4Stephanie Chen5Barnabas Desta6Alberta Hoi7Bo Ding8Christine Peschken9Jonatan Hedberg10Tina Grünfeld Eén11Alessandro Sorrentino12Danuta Kielar13BioPharmaceuticals R&D, AstraZeneca US, Gaithersburg, Maryland, USADivision of Rheumatology, Northwell Health, Great Neck, New York, USADepartment of Rheumatology. National reference Center for rare diseases (RESO). Hôpitaux Universitaires de Strasbourg et INSERM UMR-S 1109, Strasbourg, France8 Centre for Inflammatory Diseases, Monash University, Melbourne, Victoria, Australia4 Division of Rheumatology, Department of Medicine III, University Medical Center & Faculty of Medicine Carl Gustav Carus, Technical University of Dresden, Dresden, GermanyBioPharmaceuticals Medical, AstraZeneca, Gaithersburg, Maryland, USAGlobal Pricing and Market Access, AstraZeneca, Gaithersburg, Maryland, USARheumatology Research Group, Centre for Inflammatory Diseases, School of Clinical Sciences, Monash University, Clayton, Victoria, AustraliaBioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden30 Departments of Medicine and Community Health Sciences, University of Manitoba, Winnipeg, Manitoba, CanadaBioPharmaceuticals Medical Evidence and Observational Research, AstraZeneca, Gothenburg, SwedenBioPharmaceuticals Medical, AstraZeneca, Gothenburg, SwedenGlobal Medical Affairs, Respiratory & Immunology, BioPharmaceuticals Medical, AstraZeneca, Cambridge, UKBioPharmaceuticals Medical, AstraZeneca, Cambridge, UKObjectives Systemic lupus erythematosus (SLE) is a disease with heterogeneous treatment patterns largely based on organ involvement and disease severity. The SLE Prospective Observational Cohort Study (SPOCS) collected data worldwide over 3 years from patients with moderate-to-severe SLE. We report real-world patterns of medication use in patients enrolled in SPOCS.Methods Data were collected at study entry; patients were followed twice annually according to local practice. Disease activity (SLE Disease Activity Index 2000 (SLEDAI-2K)), average oral glucocorticoid dose and use of other treatments—specifically antimalarials, biologics and immunosuppressants—were measured over time. Subgroup analyses were stratified by baseline interferon gene signature (IFNGS) status and disease activity (SLEDAI-2K) status.Results Patient demographics and baseline characteristics were similar among subgroups; the majority of patients were on antimalarials (n=670; 81.1%), followed by glucocorticoids (n=537; 65.0%), immunosuppressants (n=453; 54.8%) and biologics (n=175; 21.2%). In the overall population, median (IQR) SLEDAI-2K scores decreased within 12 months (baseline: 8.0 (6.0–12.0); 12 months: 4.0 (2.0–8.0)) and remained stable thereafter. The mean (SD) daily oral glucocorticoid dose increased by 6 months (baseline: 6.0 (7.09); 6 months: 9.8 (8.67)) and remained stable thereafter. The proportion of patients who were on glucocorticoid doses >5 mg/day ranged from ~20% to 33% throughout the study. In subgroup analyses, patients with high IFNGS and high disease activity state (HDAS) at baseline used more immunosuppressants and glucocorticoids compared with those with low IFNGS and non-HDAS at baseline.Conclusions These findings underscore that SLE therapy is still often unable to reach goals as recommended by the European Alliance of Associations for Rheumatology, both with regard to glucocorticoid use and disease activity, suggesting that there is an unmet need for new treatment options for patients with SLE.Trial registration number NCT03189875; 16 June 2017.https://lupus.bmj.com/content/12/1/e001336.full |
| spellingShingle | Raj Tummala Richard A Furie Laurent Arnaud Eric F Morand Martin Aringer Stephanie Chen Barnabas Desta Alberta Hoi Bo Ding Christine Peschken Jonatan Hedberg Tina Grünfeld Eén Alessandro Sorrentino Danuta Kielar Real-world treatment patterns and clinical characteristics in patients with moderate-to-severe systemic lupus erythematosus: an analysis of the SLE Prospective Observational Cohort Study (SPOCS) Lupus Science and Medicine |
| title | Real-world treatment patterns and clinical characteristics in patients with moderate-to-severe systemic lupus erythematosus: an analysis of the SLE Prospective Observational Cohort Study (SPOCS) |
| title_full | Real-world treatment patterns and clinical characteristics in patients with moderate-to-severe systemic lupus erythematosus: an analysis of the SLE Prospective Observational Cohort Study (SPOCS) |
| title_fullStr | Real-world treatment patterns and clinical characteristics in patients with moderate-to-severe systemic lupus erythematosus: an analysis of the SLE Prospective Observational Cohort Study (SPOCS) |
| title_full_unstemmed | Real-world treatment patterns and clinical characteristics in patients with moderate-to-severe systemic lupus erythematosus: an analysis of the SLE Prospective Observational Cohort Study (SPOCS) |
| title_short | Real-world treatment patterns and clinical characteristics in patients with moderate-to-severe systemic lupus erythematosus: an analysis of the SLE Prospective Observational Cohort Study (SPOCS) |
| title_sort | real world treatment patterns and clinical characteristics in patients with moderate to severe systemic lupus erythematosus an analysis of the sle prospective observational cohort study spocs |
| url | https://lupus.bmj.com/content/12/1/e001336.full |
| work_keys_str_mv | AT rajtummala realworldtreatmentpatternsandclinicalcharacteristicsinpatientswithmoderatetoseveresystemiclupuserythematosusananalysisofthesleprospectiveobservationalcohortstudyspocs AT richardafurie realworldtreatmentpatternsandclinicalcharacteristicsinpatientswithmoderatetoseveresystemiclupuserythematosusananalysisofthesleprospectiveobservationalcohortstudyspocs AT laurentarnaud realworldtreatmentpatternsandclinicalcharacteristicsinpatientswithmoderatetoseveresystemiclupuserythematosusananalysisofthesleprospectiveobservationalcohortstudyspocs AT ericfmorand realworldtreatmentpatternsandclinicalcharacteristicsinpatientswithmoderatetoseveresystemiclupuserythematosusananalysisofthesleprospectiveobservationalcohortstudyspocs AT martinaringer realworldtreatmentpatternsandclinicalcharacteristicsinpatientswithmoderatetoseveresystemiclupuserythematosusananalysisofthesleprospectiveobservationalcohortstudyspocs AT stephaniechen realworldtreatmentpatternsandclinicalcharacteristicsinpatientswithmoderatetoseveresystemiclupuserythematosusananalysisofthesleprospectiveobservationalcohortstudyspocs AT barnabasdesta realworldtreatmentpatternsandclinicalcharacteristicsinpatientswithmoderatetoseveresystemiclupuserythematosusananalysisofthesleprospectiveobservationalcohortstudyspocs AT albertahoi realworldtreatmentpatternsandclinicalcharacteristicsinpatientswithmoderatetoseveresystemiclupuserythematosusananalysisofthesleprospectiveobservationalcohortstudyspocs AT boding realworldtreatmentpatternsandclinicalcharacteristicsinpatientswithmoderatetoseveresystemiclupuserythematosusananalysisofthesleprospectiveobservationalcohortstudyspocs AT christinepeschken realworldtreatmentpatternsandclinicalcharacteristicsinpatientswithmoderatetoseveresystemiclupuserythematosusananalysisofthesleprospectiveobservationalcohortstudyspocs AT jonatanhedberg realworldtreatmentpatternsandclinicalcharacteristicsinpatientswithmoderatetoseveresystemiclupuserythematosusananalysisofthesleprospectiveobservationalcohortstudyspocs AT tinagrunfeldeen realworldtreatmentpatternsandclinicalcharacteristicsinpatientswithmoderatetoseveresystemiclupuserythematosusananalysisofthesleprospectiveobservationalcohortstudyspocs AT alessandrosorrentino realworldtreatmentpatternsandclinicalcharacteristicsinpatientswithmoderatetoseveresystemiclupuserythematosusananalysisofthesleprospectiveobservationalcohortstudyspocs AT danutakielar realworldtreatmentpatternsandclinicalcharacteristicsinpatientswithmoderatetoseveresystemiclupuserythematosusananalysisofthesleprospectiveobservationalcohortstudyspocs |